Condition: Acute Myeloid Leukemia · B-cell Acute Lymphoblastic Leukemia · High-risk Myelodysplastic Syndrome · Sponsor: Vincerx Pharma, Inc.
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
This description comes directly from the study's public registry record.
Vincerx Clinical Trials Contact · 16508006676 · clinicaltrials@vincerx.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| TriStar Bone Marrow Transplant | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06034275